AveXis Inc. (NASDAQ:AVXS) shares saw strong trading volume on Wednesday . 184,664 shares changed hands during mid-day trading, a decline of 12% from the previous session’s volume of 209,132 shares.The stock last traded at $39.68 and had previously closed at $36.01.

Several research firms recently weighed in on AVXS. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, June 9th. Jefferies Group lowered shares of AveXis from a “buy” rating to a “hold” rating and lifted their target price for the company from $39.00 to $42.00 in a report on Wednesday, June 22nd. They noted that the move was a valuation call. Wells Fargo & Co. began coverage on shares of AveXis in a report on Friday, July 15th. They set a “market perform” rating on the stock. Goldman Sachs Group Inc. lifted their target price on shares of AveXis from $28.00 to $47.00 and gave the company a “buy” rating in a report on Friday, May 13th. Finally, Chardan Capital began coverage on shares of AveXis in a report on Monday, March 28th. They set a “buy” rating and a $60.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. AveXis presently has an average rating of “Buy” and a consensus target price of $43.80.

The company has a 50-day moving average price of $40.29 and a 200 day moving average price of $30.64. The stock’s market cap is $935.48 million.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings data on Thursday, May 12th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.89. Equities research analysts expect that AveXis Inc. will post ($3.90) earnings per share for the current fiscal year.

AveXis, Inc, formerly Biolife Cell Bank, Inc, is a clinical-stage gene therapy company. The Company operates through developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.